Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts
Rebecca H. Haberman,
Alexandra L. Rice,
Kyra Chen,
Uma Scher,
Sydney Thib,
Jose U. Scher,
Lihi Eder Arthritis and Rheumatology
· Wiley
· 2026-10-27
· DOI: 10.1002/art.70170
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Rebecca H. Haberman, Alexandra L. Rice, Kyra Chen, Uma Scher, Sydney Thib, Jose U. Scher et al. Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. // Arthritis and Rheumatology. – 2026. – DOI: 10.1002/art.70170. – URL: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70170?af=R
Rebecca H. Haberman, Alexandra L. Rice, Kyra Chen, Uma Scher, Sydney Thib, Jose U. Scher, & Lihi Eder (2026). Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis and Rheumatology. https://doi.org/10.1002/art.70170
Rebecca H. Haberman, et al. “Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.” Arthritis and Rheumatology, 2026. doi:10.1002/art.70170.
@article{Haberman2026,
title = {Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts},
author = {Haberman, Rebecca H. and Rice, Alexandra L. and Chen, Kyra and Scher, Uma and Thib, Sydney and Scher, Jose U. and Eder, Lihi},
journal = {Arthritis and Rheumatology},
year = {2026},
doi = {10.1002/art.70170},
url = {https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70170?af=R}
}
Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents in regenerative medicine, with their therapeutic effects increasingly attributed to intercellular communication and microenvironmental regulation rather than...
Background Scleral remodeling with myofibroblast activation and extracellular matrix (ECM) degradation drives myopia, but mechanisms remain unclear. This study explored USP33’s role and its regulatory network. Methods We analyzed GEO...
Background Lung cancer is one of the leading causes of cancer-related mortality worldwide. Understanding the molecular mechanisms underlying lung cancer progression is critical for identifying novel therapeutic targets. This study...